A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma

BACKGROUND: Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer. The prognostic signature could be reliable to stratify LUAD patients according to risk, which helps the management of the systematic treatments. In this study, a systematic and reliable immune signature was performed...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Dina, Wang, Mian, Shen, Zhihong, Zhu, Jiaona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060601/
https://www.ncbi.nlm.nih.gov/pubmed/32143735
http://dx.doi.org/10.1186/s12967-020-02286-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060601/
https://www.ncbi.nlm.nih.gov/pubmed/32143735
http://dx.doi.org/10.1186/s12967-020-02286-z

Ejemplares similares